Neumora Therapeutics
NMRA
93 hedge funds and large institutions have $92.2M invested in Neumora Therapeutics in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 40 reducing their positions, and 18 closing their positions.
228% more call options, than puts
Call options by funds: $600K | Put options by funds: $183K
124% more capital invested
Capital invested by funds: $41.1M → $92.2M (+$51.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.34% less ownership
Funds ownership: 34.64% → 31.3% (-3.3%)
5% less funds holding
Funds holding: 98 → 93 (-5)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
60% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.34M |
| 2 |
Millennium Management
New York
|
+$1.26M |
| 3 |
AC
AlphaCore Capital
La Jolla,
California
|
+$487K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$248K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.72M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.29M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.15M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$919K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$843K |
NMRA Hedge Fund Activity: Q3 2025 in Review
93 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q3 2025, worth a combined $92.2M — up 124% from $41.1M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of NMRA and 13 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 16 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $1.34M. The largest seller was BlackRock, cutting an estimated $1.72M.
- 93 institutional investors held Neumora Therapeutics (NMRA) as of Q3 2025, down from 98 in Q2 2025.
- Funds reported $92.2M of Neumora Therapeutics stock for Q3 2025, up 124% quarter-over-quarter.
- 13 funds opened new Neumora Therapeutics positions in Q3 2025 and 18 closed out, a net change of -5 holders.
- The largest Neumora Therapeutics buyer in Q3 2025 was Jacobs Levy Equity Management, an estimated $1.34M added.
- The largest Neumora Therapeutics seller in Q3 2025 was BlackRock, an estimated $1.72M sold.
Based on aggregated 13F filings for Q3 2025.